ライフサイエンスコーパス: clarithromycin

1 ed to serum after systemic administration of clarithromycin.

2 ulosis has intrinsic inducible resistance to clarithromycin.

3 loid cells possess a similar transporter for clarithromycin.

4 a transporter that takes up and concentrates clarithromycin.

5 tured HL-60 cells were incubated with [(3)H]-clarithromycin.

6 Mycobacterium avium complex isolates against clarithromycin.

7 ombining colchicine with medications such as clarithromycin.

8 he related outcome for patients treated with clarithromycin.

9 and SCC-25 cells were incubated with [(3)H]-clarithromycin.

10 tibiotics as erthyromycin, azithromycin, and clarithromycin.

11 dilution for the detection of resistance to clarithromycin.

12 lithromycin, a ketolide that is derived from clarithromycin.

13 eration cephalosporins, and azithromycin and clarithromycin.

14 quinolones and sulfonamides but resistant to clarithromycin.

15 the disk diffusion test with ampicillin and clarithromycin.

16 acterium to antimicrobial agents, especially Clarithromycin.

17 AC isolates, respectively, were resistant to clarithromycin.

18 for the rest), followed by ciprofloxacin and clarithromycin.

19 ting mutations associated with resistance to clarithromycin.

20 5%) by microdilution but were not found with clarithromycin.

21 he isolates were susceptible to amikacin and clarithromycin.

22 All relapse isolates were resistant to clarithromycin.

23 f resistant isolates during monotherapy with clarithromycin.

24 igilance, improved during a 2-week course of clarithromycin.

25 roton pump inhibitor (PPI), amoxicillin, and clarithromycin.

26 h hypotension (111 patients of 96,226 taking clarithromycin [0.12%] vs 68 patients of 94,083 taking a

27 kidney injury (420 patients of 96,226 taking clarithromycin [0.44%] vs 208 patients of 94,083 taking

28 ee antibiotics (ciprofloxacin ~0.0067 mg/ml, clarithromycin ~0.05 mg/ml, rifampicin ~0.002 mg/ml) cou

29 use mortality (984 patients of 96,226 taking clarithromycin [1.02%] vs 555 patients of 94,083 taking

30 n, 2 microg/ml; Bay y 3118, 0.015 microg/ml; clarithromycin, 1.25 microg/ml; D-cycloserine, 25 microg

31 The 26 isolates were susceptible to clarithromycin (100%), rifabutin (100%), ethambutol (92%

32 e the following: amikacin (14/16; 87.5%) and clarithromycin (12/16, 75.0%).

33 target ratios for ethambutol, versus 42% for clarithromycin, 19% for amikacin, 18% for rifampicin, an

34 Clarithromycin (200 mg/kg/day) was administered alone to

35 assigned active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole 500 mg, each twice

36 ylori resistance were 17% (95% CI 15-18) for clarithromycin, 44% (95% CI 39-48) for metronidazole, 18

37 examined with PMNs loaded by incubation with clarithromycin (5 mug/ml).

38 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg

39 ients were given dexamethasone 40 mg weekly, clarithromycin 500 mg twice daily, and lenalidomide 25 m

40 d omeprazole 20 mg, amoxycillin 1000 mg, and clarithromycin 500 mg, twice daily (n=142, H. pylori era

41 After 2 wk of oral clarithromycin (500 mg twice daily), secretions were aga

42 hasone (40 mg) was given orally once weekly, clarithromycin (500 mg) was given orally twice daily, an

43 ) amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2)tetracycline

44 2)tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracyc

45 ter, subjects were administered six doses of clarithromycin, 500 mg, every 12 hours.

46 controlled, double-blind, crossover trial of clarithromycin 500mg with breakfast and lunch, in patien

47 e frequent for ethambutol (48% of patients); clarithromycin (56%); and azithromycin (35%).

48 Therapy with clarithromycin, a compound commonly used to treat MAC di

49 Clarithromycin accumulates in phagocytes, monocytes, fib

50 It is feasible that clarithromycin accumulation inside PMNs could enhance th

51 [(14)C]-clarithromycin accumulation was 2.2-fold higher in RPMI

52 ide [PAbetaN], an efflux inhibitor), [(14)C]-clarithromycin accumulation, azithromycin-induced protei

53 For clarithromycin, adjustment of breakpoints based upon dis

54 Although clarithromycin administered daily resulted in a reductio

55 The activities of levofloxacin and clarithromycin against 199 penicillin- and macrolide-sus

56 this system may enhance the effectiveness of clarithromycin against invasive periodontal pathogens.

57 compounds, 38 and 57, were more active than clarithromycin against S. pneumoniae ATCC6303.

58 4 mug/mL decreased the MIC of rifampicin and clarithromycin against the same pathogens from 16 to 32

59 Pharmacodynamic indices for rifampicin, clarithromycin, amikacin, and moxifloxacin are seldom me

60 Antibiotic activity was tested for clarithromycin, amikacin, cefoxitin, tigecycline, and be

61 Clarithromycin, amoxicillin, and a pump proton inhibitor

62 ting of H. pylori isolates to metronidazole, clarithromycin, amoxicillin, and tetracycline was perfor

63 amoxicillin, twice daily for 14 days; 500 mg clarithromycin and 500 mg nitroimidazole were added, twi

64 days, followed by 40 mg pantoprazole, 500 mg clarithromycin and 500 mg tinidazole, twice daily for th

65 ound to have H. pylori isolates resistant to clarithromycin and 83 (66%) were found to have H. pylori

66 nd reduced bacillary loads in spleen whereas clarithromycin and amikacin prevented death but had litt

67 six macrolide resistant) were tested against clarithromycin and azithromycin (the latter only by BACT

68 The oral macrolides clarithromycin and azithromycin are commonly used for tr

69 of the susceptibility of H. influenzae with clarithromycin and azithromycin are highly dependent on

70 ae were tested for their susceptibilities to clarithromycin and azithromycin by the disk diffusion an

71 easured baseline characteristics between the clarithromycin and azithromycin groups.

72 Macrolides, such as clarithromycin and azithromycin, possess antimicrobial,

73 Clarithromycin and combination therapy were more effecti

74 uded intermediate ciprofloxacin MICs but low clarithromycin and doxycycline MICs of < or =1 microg/ml

75 Clarithromycin and erythromycin, but not azithromycin, i

76 t commonly prescribed antibiotic regimen was clarithromycin and ethambutol.

77 Prevalence of resistance to clarithromycin and levofloxacin rose significantly over

78 Our aim was to compare the efficacy of Clarithromycin and Levofloxacin-based sequential quadrup

79 ts with H pylori infections in areas of high clarithromycin and metronidazole resistance.

80 ternative drugs in the same class, including clarithromycin and moxifloxacin, were unknown.

81 time was not significantly different between clarithromycin and placebo.

82 The efficacy and safety of clarithromycin and rifabutin alone and in combination fo

83 Clarithromycin and rifabutin were highly protective agai

84 MICs, producing nearly twofold increases for clarithromycin and telithromycin and a greater than thre

85 tions and zwitterions (viz., the antibiotics clarithromycin and tetracycline) to dissolved humic acid

86 ing ermB- versus mefE-mediated resistance to clarithromycin and to determine the relative frequency w

87 f atorvastatin, digoxin, and erythromycin or clarithromycin and was not significantly different for c

88 were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1

89 crolide antibiotics, including erythromycin, clarithromycin, and azithromycin, are the mainstays of e

90 Macrolide antibiotics, like erythromycin, clarithromycin, and azithromycin, possess anti-inflammat

91 ntamicin, trimethoprim and sulfamethoxazole, clarithromycin, and azithromycin.

92 ria for the zone diameters for azithromycin, clarithromycin, and clindamycin that correlated well wit

93 Resistance to metronidazole, clarithromycin, and levofloxacin is more common among H.

94 The prevalence of metronidazole, clarithromycin, and levofloxacin resistance varied by re

95 erapy); 5 days of lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant therapy);

96 ential); or 5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant).

97 xicillin followed by 5 days of lansoprazole, clarithromycin, and metronidazole (sequential therapy).

98 amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole (sequential); or 5-day

99 ighly susceptible to all drugs tested except clarithromycin, and most clinical cases were successfull

100 mode) was found for amikacin, ciprofloxacin, clarithromycin, and moxifloxacin.

101 ults suggest that a combination of amikacin, clarithromycin, and rifabutin may be the most efficaciou

102 nically important antibiotics ciprofloxacin, clarithromycin, and rifampicin in the case of suspected

103 ilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin was evaluated by alter

104 a proton-pump inhibitor plus amoxicillin and clarithromycin are significantly less effective for erad

105 Metronidazole and clarithromycin are the two key antibiotics.

106 , alone or in combination with rifampicin or clarithromycin, are promising candidates for treating ba

107 c bacterial infection in a mouse model using clarithromycin as a model antibiotic and Helicobacter py

108 Among 125 mefE(+) isolates, the MIC of clarithromycin at which 90% of the isolates tested were

109 sts and epithelial cells rapidly accumulated clarithromycin, attaining steady-state intracellular con

110 to 68%, 23%, and 10% decreases in C(max) of clarithromycin, azithromycin, and moxifloxacin.

111 MICs of erythromycin, clarithromycin, azithromycin, rifampin, gentamicin, and

112 tein (cyclosporine, ketoconazole, ritonavir, clarithromycin, azithromycin, verapamil ER [extended rel

113 Clarithromycin-based regimens are commonly used as a fir

114 Among 53 persons treated with clarithromycin-based regimens, treatment failed in 77% o

115 The eradication rate obtained with Clarithromycin-based sequential treatment was significan

116 ould be considered an essential component of clarithromycin-based therapies for MAC bacteremia.

117 ilar or greater eradication rate compared to clarithromycin-based therapy.

118 ociated with a greater risk for failure with clarithromycin-based treatments.

119 fety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and de

120 ncluding the competitive effect of Ca(2+) on clarithromycin binding over a wide range of solution con

121 Clarithromycin can attain higher levels in gingiva than

122 Clarithromycin can attain higher levels in gingiva than

123 Moreover, genotypic resistance to clarithromycin can be predicted without obtaining a biop

124 This distribution profile of clarithromycin can thus be advantageous in the managemen

125 Finally, we evaluated the 3-drug combination clarithromycin, cefoxitin, and amikacin.

126 e range of MICs of several drugs, especially clarithromycin, ciprofloxacin, and sulfamethoxazole.

127 treatment with a combination of ISS-ODN and clarithromycin (CLA) was tested in vitro and in vivo.

128 0 mg 2x/day, amoxicillin 1000 mg 12/12 h and clarithromycin (CLARI) 500 mg 12/12 h, for 14 days.

129 tive effects of subgingivally delivered 0.5% clarithromycin (CLM) as an adjunct to scaling and root p

130 ic responses and possible adverse effects of clarithromycin (CLM) combined with periodontal mechanica

131 determined by Epsilometer test (E-test) for clarithromycin (CLR) and amoxicillin (AMX).

132 Results from this study indicate that a 1599 clarithromycin combination is potentially viable, provid

133 etronidazole, levofloxacin, tetracyclin, and clarithromycin, commonly used to treat H. pylori infecti

134 a calcium-channel blocker, concurrent use of clarithromycin compared with azithromycin was associated

135 These samples were analyzed for detection of clarithromycin concentration using high-performance liqu

136 Mean clarithromycin concentrations in healthy control and inf

137 after the last dose of clarithromycin, mean clarithromycin concentrations in serum and periodontal t

138 tations remains low in Marilia, the standard clarithromycin containing triple therapy is still valid.

139 oted unsatisfactory efficacy (ie, <80%) with clarithromycin-containing regimens in countries where th

140 Clarithromycin-containing regimens should be avoided in

141 The samples were extracted, and clarithromycin content was analyzed by liquid chromatogr

142 is further demonstrated in the synthesis of clarithromycin derivative, in which a tert-butyl ester i

143 Five of the 312 patients reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the

144 Concentrations of carbendazim, clarithromycin, diclofenac, and diuron exceed levels of

145 st clinical isolates confirming synergy with Clarithromycin, Doxycycline and Clindamycin, combination

146 against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, and trimethoprim-

147 against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, sulfamethoxazole,

148 posaconazole; cyclosporine; erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin.

149 valence of primary resistance of H.pylori to clarithromycin due to A2142G and A2143G mutations remain

150 PPI triple therapy (PPI + clarithromycin + either amoxicillin or metronidazole) is

151 nse to a three-times-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin.

152 For ibuprofen-clarithromycin-furosemide, the elimination profiles were

153 10 months, 32 percent of the patients in the clarithromycin group died and 41 percent of those in the

154 erapy with Levofloxacin 500 mg id instead of Clarithromycin (group B).

155 Clarithromycin had no detectable effect in either group.

156 ri-positive patients; however, resistance to clarithromycin has led to treatment failures.

157 ic modulators of GABA-A receptors, including clarithromycin, have been reported to reduce sleepiness

158 fference of 0.9 [95% CI, -1.6 to 3.3] in the clarithromycin-hydroxychloroquine group vs. the placebo

159 ne group, 35.6 (95% CI, 34.2 to 37.1) in the clarithromycin-hydroxychloroquine group, and 34.8 (95% C

160 patients in the doxycycline group, 96 in the clarithromycin-hydroxychloroquine group, and 98 in the p

161 isease or nonulcer dyspepsia); resistance to clarithromycin, imidazoles, or both; duration of triple

162 nd susceptible or intermediate to cefoxitin, clarithromycin, imipenem, and amikacin.

163 e tested once on three separate days against clarithromycin in 12B medium at pH 7.3 to 7.4 and agains

164 and undifferentiated HL-60 cells all took up clarithromycin in a saturable manner.

165 ly in infected mice, IL-12 was combined with clarithromycin in an attempt to decrease bacterial burde

166 were smaller and E-test MICs were higher for clarithromycin in CO2 than those in air, category differ

167 ot seen with levofloxacin, but occurred with clarithromycin in five strains (2.5%) by microdilution,

168 study determines the distribution profile of clarithromycin in the gingiva of patients with periodont

169 The odds of isolates being resistant to clarithromycin increased in relation to the number of co

170 One variant, associated with clarithromycin-induced arrhythmia, increases channel blo

171 Clarithromycin inhibits several periodontal pathogens an

172 Clarithromycin interaction with dissolved humic acid was

173 Clarithromycin is a well-known antibiotic that exists in

174 Clarithromycin is an inhibitor of CYP3A4 and azithromyci

175 cobacterium isolates, extended incubation in clarithromycin is necessary to determine macrolide susce

176 t is not widely prescribed by periodontists, clarithromycin is potentially useful because it is taken

177 had H pylori strains that were resistant to clarithromycin (Italy, 26%; Spain, 19.5%), 33% were resi

178 The combination of clarithromycin, lenalidomide, and dexamethasone (BiRd) w

179 Clarithromycin levels at control and gingivitis sites we

180 At steady state, clarithromycin levels inside HL-60 granulocytes and PMNs

181 nflamed sites, so it is reasonable to expect clarithromycin levels to be higher in periodontally dise

182 By increasing intracellular clarithromycin levels, this system may enhance the effec

183 Clarithromycin-loaded PMNs killed significantly more A.

184 e incubated at 37 degrees C with control and clarithromycin-loaded PMNs.

185 nted for the testing of M. fortuitum against clarithromycin; M. abscessus and M. chelonae against the

186 ional studies are needed, this suggests that clarithromycin may be a reasonable treatment option in p

187 r fluid flow at control sites suggested that clarithromycin may produce anti-inflammatory effects.

188 CLS breakpoint of 8 microg/ml in the case of clarithromycin, may explain some of the observed discord

189 Approximately 6 hours after the last dose of clarithromycin, mean clarithromycin concentrations in se

190 Acquired resistance of H. pylori to clarithromycin, metronidazole, tetracycline, and amoxici

191 4.25 microg/ml, respectively) = ethambutol > clarithromycin (MIC90, 1 microg/ml) > minocycline = doyc

192 ted [MIC90], 0.5 microgram/ml) compared with clarithromycin (MIC90, 1.5 to 2 micrograms/ml) and eryth

193 Clarithromycin MICs and MBCs for 12 isolates and 1 colon

194 Only 13 of the 356 isolates had resistant clarithromycin MICs at initial extended MIC readings, an

195 with 23S rRNA gene mutations), 85 (24%) had clarithromycin MICs of </=8 mug/ml.

196 For clarithromycin, minor discrepancies were found in three

197 patients were prescribed oral azithromycin, clarithromycin, moxifloxacin, levofloxacin, ciprofloxaci

198 sers older than 65 years who were prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) c

199 n age, 76 years) who were newly coprescribed clarithromycin (n = 96,226) or azithromycin (n = 94,083)

200 Regimen 1, omeprazole + clarithromycin (O/C), was supported by two multicenter,

201 ught to systematically assess the effects of clarithromycin on objective vigilance and subjective sle

202 intermittent therapy (n = 118) that included clarithromycin or azithromycin, rifampin, and ethambutol

203 strains resistant to either metronidazole or clarithromycin or both.

204 No association was noted between clarithromycin or ciprofloxacin and adverse cardiac outc

205 Of those in whom clarithromycin or combination therapy failed, 29% and 27

206 zithromycin, coprescription of a statin with clarithromycin or erythromycin was associated with a hig

207 In older adults, coprescription of clarithromycin or erythromycin with a statin that is met

208 d in increased activity compared with either clarithromycin or IL-12 alone in reducing the number of

209 pump inhibitor or H2 receptor blockers, plus clarithromycin or metronidazole, plus amoxicillin or tet

210 ed in 9%, 15%, and 7% of those randomized to clarithromycin or rifabutin alone or in combination, res

211 en combined with the antimycobacterial drugs clarithromycin or rifabutin, induced a decrease in bacte

212 ates at 6 months in patients receiving daily clarithromycin- or azithromycin-containing regimens.

213 ge fluid (repeated for RPMI 1640 medium with clarithromycin, other macrolides, and other gram-negativ

214 ntrol mice and 20% when IL-12 was given with clarithromycin (P < .05).

215 to demonstrate metronidazole (P < 0.05) and clarithromycin (P < 0.05) resistance.

216 ibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and traditional bismuth quadruple

217 e AIDS patients with MAC bacteremia received clarithromycin plus clofazimine, with or without ethambu

218 eceive a 12-week oral course of doxycycline, clarithromycin plus hydroxychloroquine, or placebo.

219 Clarithromycin plus IL-12 resulted in increased activity

220 Co-administration of 1599 and clarithromycin provided additional bacterial killing in

221 broad-spectrum antibiotics (azithromycin and clarithromycin, quinolones, amoxicillin-clavulanate, and

222 Although clarithromycin reduced mucus secretion in both rhinitis

223 rapy for MAC infection, and combination with clarithromycin reduces IL-12 toxicity.

224 ow rate was evident at the conclusion of the clarithromycin regimen (P = 0.018).

225 idiosis vs 30 of the 707 patients not taking clarithromycin (relative hazard [RH], 0.25 [95% confiden

226 36.2% showed point mutations associated with clarithromycin resistance (A2142C, A2142G, A2143G).

227 expected gene deletion and showed inducible clarithromycin resistance after 14 days.

228 ent susceptibility tests performed developed clarithromycin resistance after treatment.

229 Ethambutol reduced relapses and emergence of clarithromycin resistance and should be considered an es

230 les likely permitted induction of phenotypic clarithromycin resistance and subsequent loss of synergi

231 e developed to assess inducible and acquired clarithromycin resistance and tested on a total of 90 cl

232 a rapid and accurate H.pylori diagnostic and clarithromycin resistance determination method useful fo

233 ated in isolates from 222/531 (42%) persons, clarithromycin resistance in 159/531 (30%) persons, amox

234 Clarithromycin resistance is associated with a greater r

235 avoided in countries where the prevalence of clarithromycin resistance is higher than 20%.

236 azole) is restricted to areas with known low clarithromycin resistance or high eradication success wi

237 n-containing regimens in countries where the clarithromycin resistance rates were higher than 20%.

238 Phenotypic detection of clarithromycin resistance requires extended incubation (

239 s group, a multiplex real-time PCR assay for clarithromycin resistance showed 95% (38/40) concordance

240 The clarithromycin resistance suggested the presence of an i

241 MAG can display clarithromycin resistance through the inducible erm(41)

242 Median time to clarithromycin resistance was 16 weeks with two drugs an

243 Clarithromycin resistance was determined upon analysis o

244 een isolates showed rrl mutations conferring clarithromycin resistance, including A2058G (11 isolates

245 2C mutation potentially conferring low-level clarithromycin resistance, while levels of metronidazole

246 pylori isolates demonstrated a high invitro clarithromycin resistance.

247 V of the H. pylori 23S rDNA associated with clarithromycin resistance.

248 infection in an area with high prevalence of clarithromycin resistance.

249 M. bolletii and the assessment of inducible clarithromycin resistance.

250 Prevalence of H.pylori with clarithromycin resistant genotypes was 2,46%, with predo

251 ally due to emergency cases and increases of clarithromycin resistant strains.

252 in combination, were evaluated against both clarithromycin-resistant (CLR-R) and CLR-susceptible (CL

253 s, treatment failed in 77% of those carrying clarithromycin-resistant H. pylori (10 of 13) and 13% of

254 sponsible for community-acquired infections, clarithromycin-resistant Helicobacter pylori, and fluoro

255 ntified 51 patients over a 15-yr period with clarithromycin-resistant MAC (minimum inhibitory concent

256 The frequency of clarithromycin-resistant MAC in mice receiving the combi

257 Risk of MAC disease was reduced by 44% with clarithromycin (risk ratio [RR], 0.56; 95% CI, 0.37-0.84

258 mmatory activity of 3 macrolide antibiotics, clarithromycin, roxithromycin, and azithromycin, in an i

259 bination therapy was not more effective than clarithromycin (RR, 0.79; 95% CI, 0.48-1.31; P=.36).

260 of forty-seven H. pylori isolates cultured, clarithromycin sensitivity was present in 30(64%) and am

261 ral or parenteral macrolide (azithromycin or clarithromycin) served as the comparison group.

262 o: 14 days of lansoprazole, amoxicillin, and clarithromycin (standard therapy); 5 days of lansoprazol

263 We recommend that clarithromycin susceptibility breakpoints for M. abscess

264 resence of Helicobacter pylori and determine clarithromycin susceptibility in paraffin-embedded biops

265 A standardized clarithromycin susceptibility test for Mycobacterium gen

266 Clarithromycin susceptibility testing of MAC using the S

267 as Health Science Center at Tyler) underwent clarithromycin susceptibility testing with readings at 3

268 d, like M. chelonae, do not require extended clarithromycin susceptibility testing.

269 Forty-two isolates were classified as clarithromycin susceptible and all isolates were classif

270 However, only 21 isolates were clarithromycin susceptible at pH 7.2 and 34 isolates wer

271 t H. pylori (10 of 13) and 13% of those with clarithromycin-susceptible strains (5 of 40) (relative r

272 eradication therapy who were taking O/C with clarithromycin-susceptible strains before treatment and

273 In contrast to clarithromycin, tetracycline binding to humic acid incre

274 but was the only side effect more common on clarithromycin than placebo.

275 After clarithromycin, the rheology, hydration, cohesion, and t

276 At each site, strains were tested against clarithromycin three times on each of three separate day

277 s of resistance; susceptibility to amikacin, clarithromycin, tobramycin (only in M. chelonae), and ce

278 We assayed clarithromycin transport by measuring cell-associated ra

279 Clarithromycin transport exhibited Michaelis-Menten kine

280 Clarithromycin transport was assayed by measuring change

281 roups: 14-day lansoprazole, amoxicillin, and clarithromycin (triple therapy); 5-day lansoprazole and

282 pantoprazole, 1000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7 days; iDU sequential t

283 ne and 3 days after administration of 500 mg clarithromycin, twice daily, for 3 days.

284 study was to characterize the mechanisms of clarithromycin uptake by gingival fibroblasts and oral e

285 companion drugs, with no risk difference in clarithromycin versus azithromycin and daily versus inte

286 of sleepiness were significantly improved on clarithromycin versus placebo.

287 Thus, both types of cells take up clarithromycin via a concentrative active transport syst

288 Coprescribing clarithromycin vs azithromycin with a calcium-channel bl

289 therapy using omeprazole, metronidazole, and clarithromycin was administered p.o. at 8, 12, or 22 WPI

290 Coprescription with clarithromycin was also associated with a higher risk of

291 Resistance to clarithromycin was associated with previous use of any m

292 Clarithromycin was less active at pH 7.2 against 43% of

293 Regimen 2, ranitidine-bismuth-citrate + clarithromycin, was supported by two multicenter, placeb

294 with constitutive resistance to amikacin and clarithromycin were isolated from several individuals ne

295 ces were minor, and susceptibility rates for clarithromycin were similar to those obtained by agar an

296 c acid, cefdinir, cefixime, ceftriaxone, and clarithromycin were the most reproducible.

297 C breakpoints as being identical to those of clarithromycin, which resulted in equivalent cross-susce

298 HL-60 granulocytes transported clarithromycin with a K(m) of approximately 250 mug/ml a

299 in purulent rhinitis, we questioned whether clarithromycin would change the properties of nasal mucu

300 Incubation in medium containing 2 mug/mL clarithromycin yielded steady-state intracellular concen